Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Evolus, Inc. (NASDAQ:EOLS) have been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $14.50.

A number of equities analysts have commented on EOLS shares. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Evolus in a report on Tuesday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total value of $950,176.32. Following the transaction, the insider owned 499,592 shares of the company’s stock, valued at $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.00% of the stock is owned by corporate insiders.

Institutional Trading of Evolus

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC bought a new stake in shares of Evolus in the 2nd quarter worth approximately $71,000. WINTON GROUP Ltd bought a new position in Evolus during the 2nd quarter worth $77,000. Squarepoint Ops LLC grew its stake in Evolus by 24.8% during the 2nd quarter. Squarepoint Ops LLC now owns 197,708 shares of the company’s stock worth $1,372,000 after buying an additional 39,316 shares during the last quarter. Angeles Wealth Management LLC acquired a new stake in Evolus in the second quarter worth $732,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in Evolus in the second quarter worth $193,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Trading Down 1.7%

Shares of NASDAQ EOLS opened at $7.86 on Friday. The company has a market capitalization of $519.15 million, a price-to-earnings ratio of -15.12 and a beta of 1.42. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31. The business has a 50 day simple moving average of $7.68 and a 200-day simple moving average of $6.44.

About Evolus

Evolus, Inc is a medical aesthetics company focused on developing and commercializing products for healthcare professionals and consumers. The company’s business is centered on aesthetic treatments designed to address facial lines, wrinkles, skin quality and other signs of aging.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines.” The company markets Jeuveau through its physician-focused Evolus Aesthetic Center platform and related digital tools, education and patient-engagement services.

The company has expanded beyond neuromodulators into dermal fillers and other aesthetic products, including its Evolysse hyaluronic acid filler portfolio.